Abstract

Clinical molecular laboratory professionals are at the frontline of the response to the severe acute respiratory pattern coronavirus 2 (SARS- CoV- 2) epidemics, furnishing accurate, high- quality laboratory results to prop in opinion, treatment, and epidemiology. In this part, we've encountered multitudinous nonsupervisory, payment, forcechain, logistical, and systems challenges that we've plodded to overcome to fulfil our calling to give patient care. In this Perspective from the Association for Molecular Pathology Infectious Disease Subdivision Leadership platoon, we review how our members have risen to these challenges, give recommendations for managing the current epidemic, and outline the way we can take as a community to more prepare for unborn afflictions. There are numerous factors as to why the response to severe acute respiratory pattern coronavirus 2( SARS- CoV- 2) in the United States has been different from former epidemic responses, and the thing herein is to validate challenges to the SARS- CoV- 2 response and give original recommendations to more prepare for the coming epidemic. In 2009, the influenza A H1N1 epidemic was the first epidemic in the age of molecular diagnostics. The large network of academic and community sanitarium laboratories throughout the United States was suitable to develop and validate molecular tests in the first week of the outbreak to rule out H1N1 as the cause of a case's illness, and this played a critical part in containing the H1N1 epidemic. For illustration, in Chicago, IL, during the first month of the epidemic, 62 of the cases screened for H1N1 influenza were tested by community molecular diagnostics laboratories, with a typical reversal time of 24 hours. The clinical laboratory community fleetly handed extensively available H1N1 influenza molecular testing, easing a nippy epidemic response.